DNA 합성 시장 : 규모, 점유율, 동향 분석, 서비스 유형별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

DNA Synthesis Market Size, Share & Trends Analysis Report By Service Type (Gene Synthesis, Oligonucleotide Synthesis), By Application (Research Development, Diagnostics), By End use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,521,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,953,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,818,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

DNA 합성 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 DNA 합성 시장 규모는 2033년까지 138억 5,000만 달러에 이르고, 2025년부터 2033년까지의 CAGR은 16.89%를 나타낼 것으로 예측됩니다.

이 성장은 환자의 치료를 결정하는 데 도움이되는 개인화 유전체 시퀀싱에 대한 관심 증가로 인한 것입니다. 또한, DNA 합성은 질병 모니터링, 의약품 및 약리 유전체학에 대한 광범위한 응용을위한 생물학적 연구 활동에 혁명을 일으킬 수있는 능력을 가지고 있습니다.

COVID-19의 유행성은 COVID-19 감염과 다양한 유형의 암 치료를위한 mRNA 기반 백신의 채택에 긍정적인 영향을 미쳤습니다. 또한 COVID-19 연구의 주요 초점은 DNA 합성입니다. 합성 DNA는 모든 PCR 분석에 사용됩니다.

효소 공학의 개발은 효소적 DNA 합성을 위한 다양한 접근법의 개발을 뒷받침하고 있습니다. Biolabs는 10,000 염기쌍의 DNA 서열을 합성하는 임무를 설정하고 2021년 12월까지 20,000 염기쌍의 DNA 분자라는 이정표를 달성했습니다.

유전자 합성은 특정 nucleotides 서열에 의한 표적 돌연변이 유발이나 원하는 표현형 발현의 제어 등 폭넓은 용도가 있습니다.

Oligonucleotide 합성은 핵산의 비교적 짧은 단편을 필요로 하는 결정적인 서열로 실험실 기반으로 생산하는 것입니다. Ribbon Biolabs사는 다양한 Oligonucleotide 라이브러리를 이용한 nucleotide 분자의 합성에 관한 Ribbon Biolabs사의 방법에 관한 미국 특허를 취득했다고 발표했습니다.

DNA 합성 시장 보고서의 하이라이트

• 2024년에는 oligonucleotide 합성 부문이 업계를 지배했습니다.
• 연구개발 부문은 2024년에 63.49%의 수익 점유율로 시장을 독점했습니다.
• 바이오의약품·진단약 기업 부문은 2024년에 49.63%의 수익 점유율로 시장을 독점했습니다.
• 북미가 시장을 독점해 2024년의 매출 점유율은 39.83%였습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 DNA 합성 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/보조 시장 전망.
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• DNA 합성 시장 분석 도구
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 DNA 합성 시장 : 서비스 유형의 추정 및 예측 분석

• 부문 대시보드
• 세계의 DNA 합성 시장의 서비스 유형 변동 분석
• 세계의 DNA 합성 시장 규모와 동향 분석(서비스 유형별, 2021-2033년)
• oligonucleotide 합성
  • 유형별
  • 길이별
• 유전자 합성
  • 유형별
  • 길이별

제5장 DNA 합성 시장 : 용도의 추정 및 예측 분석

• 부문 대시보드
• 세계의 DNA 합성 시장의 용도 변동 분석
• 세계의 DNA 합성 시장 규모와 동향 분석(용도별, 2021-2033년)
• 연구개발
  • oligonucleotide 합성
  • 유전자 합성
• 진단
• 치료제
  • RNAi 요법
  • 안티센스 및 oligonucleotide 기반 치료법
  • 기타

제6장 DNA 합성 시장 : 최종 용도의 추정 및 예측 분석

• 부문 대시보드
• 세계의 DNA 합성 시장의 최종 용도 변동 분석
• 세계의 DNA 합성 시장 규모와 동향 분석(최종 용도별, 2021-2033년)
• 바이오의약품·진단약 기업
• 학술연구기관
• 계약연구기관

제7장 DNA 합성 시장 : 지역의 추정 및 예측 분석

• 지역별 시장 점유율 분석, 2024년 및 2033년
• 지역 시장 대시보드
• 시장 규모, 예측 동향 분석, 2021-2033년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 기업/경쟁의 분류
• 전략 매핑
• 기업시장 포지셔닝 분석, 2024년
• 기업 프로파일/상장 기업
  • Thermo Fisher Scientific. Inc.
  • Twist Bioscience
  • BIONEER CORPORATION
  • Eton Bioscience, Inc.
  • LGC Biosearch Technologies
  • IBA Lifesciences GmbH
  • Eurofins Scientific
  • Integrated DNA Technologies, Inc.
  • Quintara Biosciences
  • GenScript

SHW

영문 목차

영문목차

DNA Synthesis Market Growth & Trends:

The global DNA synthesis market size is expected to reach USD 13.85 billion by 2033, registering a CAGR of 16.89% from 2025 to 2033, according to a new report by Grand View Research, Inc. The growth is due to the rising focus on personalized genome sequencing that aids determine patient care. In addition, DNA synthesis has the capability to revolutionize biological research activities for widespread applications in disease monitoring, drug discovery, and pharmacogenomics.

The COVID-19 pandemic positively impacted the adoption of mRNA-based vaccines for the treatment of COVID-19 infection and different types of cancers. The utility of mRNA boosts the demand for synthetic DNA. Furthermore, a major focus of Covid-19 research is DNA synthesis. Synthetic DNA is used in all PCR analyses. Patients need to use a DNA primer to identify any genomic DNA that may be present in the sample.

Progress in enzyme engineering is boosting the development of different approaches for enzymatic DNA synthesis. It involves the use of enzymes to chain the nucleic acids together in the required sequence and requires further optimization for its widespread applications. Many market players are striving to devise novel technologies for efficient enzymatic production of nucleotides in the lowest turnaround time. For instance, in May 2021, Ribbon Biolabs set a mission of synthesizing DNA sequences of 10,000 base pairs and accomplished a milestone of a 20,000 base pair DNA molecule by December 2021.

Gene synthesis has a broad spectrum of applications in targeted mutagenesis with a specific sequence of nucleotides along with the regulation of a desired phenotypic expression. It forms the primary basis of genetic engineering, which has significantly leveraged the scope and quality of antibodies by the development of antibody fragments with high specificity.

Oligonucleotide synthesis is the laboratory-based production of relatively short fragments of nucleic acids in a required definitive sequence. The technique is an extremely robust practice that facilitates rapid and inexpensive access to the custom-made oligonucleotides of the desired sequence. Companies have devised their oligonucleotide libraries to aid their nucleotide synthesis processes. For instance, in July 2022, Ribbon Biolabs declared that it secured a U.S. Patent that comprises Ribbon Biolabs' method for the synthesis of a nucleotide molecule using a diverse library of oligonucleotides. The approach comprises a pre-built library of oligonucleotides for efficient access.

DNA Synthesis Market Report Highlights:

• The oligonucleotide synthesis segment dominated the industry in 2024. The larger share of this segment can be attributed to the focus on genomics research, personalized medicine, and understanding the genetic basis of diseases.
• The research and development segment dominated the market with a revenue share of 63.49% in 2024, owing to the growing use of DNA synthesis to support ongoing research studies across the globe.
• The biopharmaceutical and diagnostics companies segment dominated the market with a revenue share of 49.63% in 2024. Biopharmaceutical companies involved in the DNA synthesis market regularly use gene synthesis as an engineering tool to design and produce new DNA sequences & protein functions of interest.
• North America dominated the market and accounted for a 39.83% revenue share in 2024. The region experiences market growth due to heightened public awareness, robust medical facilities, and substantial R&D investments.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service Type
  • 1.2.2. Application
  • 1.2.3. End use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. DNA Synthesis Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. DNA synthesis Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. DNA Synthesis Market: Service Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global DNA Synthesis Market Service Type Movement Analysis
• 4.3. Global DNA Synthesis Market Size & Trend Analysis, by Service Type, 2021 to 2033 (USD Million)
• 4.4. Oligonucleotide synthesis
  • 4.4.1. Oligonucleotides synthesis market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.2. By Type
    • 4.4.2.1. Standard oligonucleotides synthesis
      • 4.4.2.1.1. Standard oligonucleotides synthesis market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2.2. Custom oligonucleotide synthesis
      • 4.4.2.2.1. Custom oligonucleotides synthesis market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.3. By Length
    • 4.4.3.1. Less than 50nt
      • 4.4.3.1.1. Less than 50nt market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3.2. 51-100nt
      • 4.4.3.2.1. 51-100nt market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3.3. 101-150nt
      • 4.4.3.3.1. 101-150nt synthesis market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3.4. More than 150nt
      • 4.4.3.4.1. More than 150nt synthesis market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Gene synthesis
  • 4.5.1. Gene synthesis market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.2. By Type
    • 4.5.2.1. Custom gene synthesis
      • 4.5.2.1.1. Custom gene synthesis market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.2.2. Gene library synthesis
      • 4.5.2.2.1. Gene library synthesis market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.3. By Length
    • 4.5.3.1. Less than 500nt
      • 4.5.3.1.1. Less than 500nt market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.3.2. 501-1000nt
      • 4.5.3.2.1. 501-1000nt market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.3.3. 1001-1500nt
      • 4.5.3.3.1. 1001-1500nt synthesis market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.3.4. 1501-2000nt
      • 4.5.3.4.1. 1501-2000nt synthesis market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.3.5. 2001-2500nt
      • 4.5.3.5.1. 2001-2500nt synthesis market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.3.6. More than 2500nt
      • 4.5.3.6.1. More than 2500nt synthesis market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. DNA Synthesis Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global DNA Synthesis Market Application Movement Analysis
• 5.3. Global DNA Synthesis Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Research & Development
  • 5.4.1. Research & development market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.2. Oligonucleotide synthesis
    • 5.4.2.1. Oligonucleotide synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2.2. PCR
      • 5.4.2.2.1. PCR synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2.3. NGS
      • 5.4.2.3.1. NGS synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2.4. CRISPR
      • 5.4.2.4.1. CRISPR synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2.5. Cloning and mutagenesis
      • 5.4.2.5.1. Cloning and mutagenesis synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2.6. Others
      • 5.4.2.6.1. Others synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.3. Gene synthesis
    • 5.4.3.1. Gene synthesis market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.3.2. Synthetic biology
      • 5.4.3.2.1. Synthetic biology tumors market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.3.3. Vaccine development
      • 5.4.3.3.1. Vaccine development synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.3.4. Genetic engineering
      • 5.4.3.4.1. Genetic engineering synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.3.5. Others
      • 5.4.3.5.1. Others synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Diagnostics
  • 5.5.1. Diagnostics market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Therapeutics
  • 5.6.1. Therapeutics market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6.2. RNAi therapies
    • 5.6.2.1. RNAi therapies market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6.3. Antisense and oligonucleotide-based therapies
    • 5.6.3.1. Antisense and oligonucleotide-based therapies market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6.4. Others
    • 5.6.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. DNA Synthesis Market: End use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global DNA Synthesis Market End use Movement Analysis
• 6.3. Global DNA Synthesis Market Size & Trend Analysis, by End use, 2021 to 2033 (USD Million)
• 6.4. Biopharmaceutical & Diagnostic Companies
  • 6.4.1. Biopharmaceutical & diagnostic companies market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Academic & Research Institutes
  • 6.5.1. Academic & research institutes market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Contract Research Organizations
  • 6.6.1. Contract Research Organizations market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. DNA Synthesis Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Competitive scenario
    • 7.4.1.3. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Canada
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. Mexico
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Competitive scenario
    • 7.5.1.3. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. Germany
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. France
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Italy
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. Spain
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Norway
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Competitive scenario
    • 7.5.8.3. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Competitive scenario
    • 7.6.1.3. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. India
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. Australia
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. Thailand
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Competitive scenario
    • 7.7.1.3. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Argentina
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Competitive scenario
    • 7.8.1.3. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.3. UAE
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.4. Kuwait
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Thermo Fisher Scientific. Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Service benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Twist Bioscience
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Service benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. BIONEER CORPORATION
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Service benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Eton Bioscience, Inc.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Service benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. LGC Biosearch Technologies
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Service benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. IBA Lifesciences GmbH
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Service benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Eurofins Scientific
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Service benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Integrated DNA Technologies, Inc.
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Service benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Quintara Biosciences
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Service benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. GenScript
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Service benchmarking
    • 8.4.10.4. Strategic initiatives

관련자료